Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design (Q44141083)
Jump to navigation
Jump to search
scientific article published on 16 September 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design |
scientific article published on 16 September 2002 |
Statements
1 reference
Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design (English)
1 reference
Joseph G Joyce
1 reference
William M Hurni
1 reference
Michael J Bogusky
1 reference
Victor M Garsky
1 reference
Xiaoping Liang
1 reference
Michael P Citron
1 reference
Renee C Danzeisen
1 reference
Michael D Miller
1 reference
John W Shiver
1 reference
Paul M Keller
1 reference
16 September 2002
1 reference
1 reference
277
1 reference
48
1 reference
45811-45820
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference